Necitumumab in metastatic squamous cell lung cancer

JAMA Oncology

Volumn 1, Issue 9, 2015, Pages 1293-1300

  Goldstein, Daniel A ^a   Chen, Qiushi ^b   Ayer, Turgay ^b   Howard, David H ^a,c   Lipscomb, Joseph ^a,c   Ramalingam, Suresh S ^a   Khuri, Fadlo R ^a   Flowers, Christopher R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; NECITUMUMAB;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; ECONOMICS; HUMAN; LUNG NEOPLASMS; MARKOV CHAIN; MEDICARE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; DRUG COSTS; HUMANS; LUNG NEOPLASMS; MARKOV CHAINS; MEDICARE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 84983516579     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.3316     Document Type: Article

References (52)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing inwomen. Lung Cancer. 2014;84(1):13-22.
3. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
4. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12 (8):735-742.
5. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
6. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489 (7417):519-525.
7. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550.
8. Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346 (2):92-98.
9. Scagliotti GV, De Marinis F, Rinaldi M, et al; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20(21):4285-4291.
10. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19(13):3210-3218.
11. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-3024.
12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-3551.
13. Dienstmann R, Tabernero J. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs. 2010;11(12):1434-1441.
14. Thatcher N, Hirsch FR, Luft AV, et al; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763-774.
15. Paz-Ares L, Mezger J, Ciuleanu TE, et al; INSPIRE Investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015;16(3): 328-337.
16. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277-1280.
17. Surveillance, Epidemiology, and End Results Program. SEER data, 1973-2012 (including July-December 2005 Hurricane Katrina Impacted Louisiana Cases). http://seer.cancer.gov/data/. Accessed July 23, 2015.
18. HoyleMW, HenleyW. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11(139):139.
19. Auget J-L, Balakrishnan N, Mesbah M, Molenberghs G. Advances in Statistical Methods for the Health Sciences. Berlin, Germany: Springer; 2007.
20. Arias E. United States life tables, 2010. Natl Vital Stat Rep. 2014;63(7):1-63.
21. Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997-1003.
22. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683-690.
23. Medicare ASP Drug Pricing Files. 2014; http://www.cms.gov/Medicare/Medicare-Fee-for -Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice /2014ASPFiles.html. Accessed December 3, 2014.
24. Curtiss FR, Lettrich P, Fairman KA. What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm. 2010;16(7):492-501.
25. Goldstein DA, Chen Q, Ayer T, et al. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol. 2015;33(10):1112-1118.
26. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14(6):836-845.
27. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: the TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354-2362.
28. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353 (2):123-132.
29. Furuse K, FukuokaM, Kuba M, et al; The Japan Vinorelbine Lung Cancer Cooperative Study Group. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). Ann Oncol. 1996;7(8):815-820.
30. Centers for Disease Control and Prevention Faststats Homepage. http://www.cdc.gov/nchs /fastats/bodymeas.htm. Accessed October 11, 2013.
31. Medicare Physician Fee Schedule. 2014; https://www.cms.gov/Medicare/Medicare-Fee-for-Service -Payment/PhysicianFeeSched/index.html ?redirect=/PhysicianFeeSched/. Accessed December 3, 2014.
32. Tumeh JW, Moore SG, Shapiro R, Flowers CR. Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2005;5 (2):153-162.
33. Briggs A, Claxton C, Sculpher M. Decision Modeling for Health Economic Evaluation. Oxford, England: Oxford University Press; 2006.
34. WinkelmayerWC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22(5): 417-430.
35. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009;12(1):80-87.
36. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50, 000-per-QALY threshold.NEngl J Med. 2014;371(9):796-797.
37. Bach P. Cancer: Unpronounceable Drugs, Incomprehensible Prices. http://www.forbes.com /sites/matthewherper/2014/08/13/cancer -unpronounceable-drugs-incomprehensible-prices /. Accessed July 23, 2015.
38. US Dept of Health and Human Services. Better, Smarter, Healthier: In historic announcement, HHS sets clear goals and timeline for shifting Medicare reimbursements from volume to value [press release, January 26, 2015]. http://www.hhs.gov /news/press/2015pres/01/20150126a.html. Accessed July 23, 2015.
39. Centers for Medicare & Medicaid Services. Oncology care model. http://innovation.cms.gov /initiatives/Oncology-Care/. Accessed March 19, 2015.
40. Elkin EB, Bach PB. Cancer's next frontier: addressing high and increasing costs. JAMA. 2010; 303(11):1086-1087.
41. Berwick DM. Making good on ACOs' promise: the final rule for the Medicare shared savings program. N Engl J Med. 2011;365(19):1753-1756.
42. de Souza JA, Polite BN, ManningWG, Fendrick AM, Ratain MJ. Value-based insurance design in oncology. Lancet Oncol. 2011;12(4):321-323.
43. Schmidt H, Emanuel EJ. Lowering medical costs through the sharing of savings by physicians and patients: inclusive shared savings. JAMA Intern Med. 2014;174(12):2009-2013.
44. Kupferschmidt K. Germanymoves to lower drug prices. CMAJ. 2011;183(2):E77-E78.
45. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992;116(3):177-182.
46. Welch HG. Valuing clinical strategies early in their development. Ann Intern Med. 1992;116(3): 263-264.
47. Gandjour A. Convergence of decision rules for value-based pricing of new innovative drugs [published online October 18, 2014]. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):209-213.
48. Gandjour A. Reference pricing and price negotiations for innovative new drugs: viable policies in the long term? Pharmacoeconomics. 2013;31(1):11-14.
49. Saret CJ, Winn AN, Shah G, et al. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015;125(12):1866-1869.
50. Chhatwal J, Mathisen M, Kantarjian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 2015.
51. Medicare Payment Advisory Commission. Report To the Congress: Medicare Payment Policy: March 2014. http://www.medpac.gov/-documents -/reports. Accessed July 23, 2015.
52. FriedbergM, Saffran B, Stinson TJ, NelsonW, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;282(15):1453-1457.